ChiCTR2100051981 版本V2.2 版本创建时间2022/06/27 13:21:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100051981 

最近更新日期:

Date of Last Refreshed on:

2022-06-27 13:21:27 

注册时间:

Date of Registration:

2021-10-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

麦粒灸治疗乙肝肝硬化腹水临床随机对照试验

Public title:

Clinical randomized controlled trial on treatment of ascites due to hepatitis B cirrhosis by grain-sized moxibustion

注册题目简写:

English Acronym:

研究课题的正式科学名称:

麦粒灸治疗乙肝肝硬化腹水临床随机对照试验

Scientific title:

Clinical randomized controlled trial on treatment of ascites due to hepatitis B cirrhosis by grain-sized moxibustion

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2200006258

申请注册联系人:

徐笑 

研究负责人:

李君 

Applicant:

Xu Xiao 

Study leader:

Li Jun 

申请注册联系人电话:

Applicant telephone:

+86 15510051696

研究负责人电话:

Study leader's
telephone:

+86 15210976313

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

945840060@qq.com

研究负责人电子邮件:

Study leader's E-mail:

945840060@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区内南小街16号

研究负责人通讯地址:

北京市东城区内南小街16号

Applicant address:

16 Nanxiaojie Street, Dongcheng District, Beijing, China

Study leader's address:

16 Nanxiaojie Street, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100700

研究负责人邮政编码:

Study leader's postcode:

100700

申请人所在单位:

中国中医科学院中国医史文献研究所

Applicant's institution:

Institute of Chinese Medical History and Literature, China Academy of Chinese Medical Sciences

研究负责人所在单位:

中国中医科学院中国医史文献研究所

Affiliation of the Leader:

Institute of Chinese Medical History and Literature, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-1007-82-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海中医药大学附属曙光医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021-08-25 00:00:00

伦理委员会联系人:

吕佳

Contact Name of the ethic committee:

Lyu Jia

伦理委员会联系地址:

上海市浦东新区张衡路528号

Contact Address of the ethic committee:

528 Zhangheng Road, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 20256070

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属曙光医院

Primary sponsor:

Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市浦东新区张衡路528号

Primary sponsor's address:

528 Zhangheng Road, Pudong New Area, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院中国医史文献研究所

具体地址:

东城区内南小街16号

Institution
hospital:

Institute of Chinese Medical History and Literature, China Academy of Chinese Medical Sciences

Address:

16 Nanxiaojie Street, Dongcheng District

经费或物资来源:

专项项目经费

Source(s) of funding:

Special project funds

研究疾病:

肝硬化腹水  

Target disease:

Cirrhotic ascites

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机交叉对照 

Study design:

Cross-over 

研究目的:

主要目的:根据前期研究成果、临床观察及名家经验拟定麦粒灸治疗方案,通过临床随机对照试验,深入观察并验证麦粒灸疗法对乙肝肝硬化腹水的临床效果和安全性,探索形成治疗乙肝肝硬化腹水的新方案。  

Objectives of Study:

Main purpose: according to the previous research results, clinical observations and experience of famous experts to formulate a treatment plan of wheat grain moxibustion, through clinical randomized controlled trials, in-depth observation and verification of the clinical effect and safety of wheat grain moxibustion therapy on hepatitis B cirrhosis ascites, to explore the formation of treatment for hepatitis B A new protocol for cirrhotic ascites.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合乙肝肝硬化腹水西医诊断标准者;
2.年龄18~75岁者,男女不限;
3.患者自愿参加本项研究,签署知情同意书;
4.意识清晰、能表达主观不适症状者。

Inclusion criteria

1.Patients who meet the diagnostic criteria of western medicine for hepatitis B cirrhosis and ascites;
2.Aged 18 to 75 years, male or female;
3.Patients voluntarily participated in this study and signed the informed consent;
4.Clear consciousness, can express subjective discomfort symptoms.

排除标准:

1.精神病患者;
2.合并心力衰竭、呼吸衰竭、严重肾功能不全及合并其他严重感染性疾病者;
3.有严重出血倾向者;
4.孕妇及哺乳期妇女;
5.正在进行其他临床研究者或研究者认为不适合参加研究的其他情况。

Exclusion criteria:

1.Psychopath;
2.Combined with heart failure, respiratory failure, severe renal insufficiency and other serious infectious diseases;
3.Patients with severe bleeding tendency;
4.Pregnant women and lactating women;
5.Other clinical investigators or other conditions that the investigator considers unsuitable to participate in the study.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2023-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-23 00:00:00 To 2022-12-01 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

34

Group:

The treatment group

Sample size:

干预措施:

麦粒灸

干预措施代码:

Intervention:

moxibustion with seed-sized moxa cone

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属曙光医院 

单位级别:

三级甲等 

Institution
hospital:

Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疾病疗效

指标类型:

主要指标

Outcome:

Disease curative effect

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Child-Pugh评分

指标类型:

次要指标

Outcome:

Child - Pugh score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症状评分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine symptom score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹围

指标类型:

次要指标

Outcome:

Abdomen circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

Weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

24小时尿量

指标类型:

次要指标

Outcome:

Urine volume in 24 hours

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

次要指标

Outcome:

Blood coagulation function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电解质检查

指标类型:

次要指标

Outcome:

Electrolyte test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

3个月内因腹水加重再入院率

指标类型:

次要指标

Outcome:

Readmission rate due to ascites within 3 months

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由受试者随机抽签产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequences are generated by random drawing of subjects.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

No

Blinding:

No

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不适用。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

不适用。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not applicable.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-11 01:32:30